An experimental target-based platform in yeast for screening Plasmodium vivax deoxyhypusine synthase inhibitors Authors: Suélen Fernandes Silva, Angélica Hollunder Klippel, Sunniva Sigurdardóttir, Sayyed Jalil Mahdizadeh, Ievgeniia Tiukova, Catarina Bourgard, Luis Carlos Salazar-Alvarez, Heloísa Monteiro do Amaral Prado, Renan Vinicius de Araujo, Fabio Trindade Maranhão Costa, Elizabeth Bilsland, Ross D. King, Katlin Brauer Massirer, Leif A. Eriksson, Mário Henrique Bengtson, Cleslei Fernando Zanelli, Per Sunnerhagen, Shaden Kamhawi, Shaden Kamhawi, Shaden Kamhawi Published: 2024 ABSTRACT The enzyme deoxyhypusine synthase (DHS) catalyzes the first step in the post-translational modification of the eukaryotic translation factor 5A (eIF5A). This is the only protein known to contain the amino acid hypusine, which results from this modification. Both eIF5A and DHS are essential for cell viability in eukaryotes, and inhibiting DHS is a promising strategy to develop new therapeutic alternatives. DHS proteins from many are sufficiently different from their human orthologs for selective targeting against infectious diseases; however, no DHS inhibitor selective for parasite orthologs has previously been reported.Here, we established a yeast surrogate genetics platform to identify inhibitors of DHS from Plasmodium vivax, one of the major causative agents of malaria. We constructed genetically modified Saccharomyces cerevisiae strains expressing DHS genes from Homo sapiens (HsDHS) or P. vivax (PvDHS) in place of the endogenous DHS gene from S. cerevisiae. Compared with a HsDHS complemented strain with a different genetic background that we previously generated, this new strain background was ~60-fold more sensitive to an inhibitor of human DHS.Initially, a virtual screen using the ChEMBL-NTD database was performed. Candidate ligands were tested in growth assays using the newly generated yeast strains expressing heterologous DHS genes. Among these, two showed promise by preferentially reducing the growth of the PvDHS-expressing strain. Further, in a robotized assay, we screened 400 compounds from the Pathogen Box library using the same S. cerevisiae strains, and one compound preferentially reduced the growth of the PvDHS-expressing yeast strain. Western blot revealed that these compounds significantly reduced eIF5A hypusination in yeast. The compounds showed antiplasmodial activity in the asexual erythrocyte stage; EC50 in high nM to low μM range, and low cytotoxicity.Our study demonstrates that this yeast-based platform is suitable for identifying and verifying candidate small molecule DHS inhibitors, selective for the parasite over the human ortholog. Introduction Annually, ~ 250 million cases of malaria are reported, predominantly in low and middle-income countries, resulting in over 600,000 deaths [1]. Despite increased investments in malaria research and disease control over the past century, transmission rates remain high. Furthermore, the prognosis is expected to worsen due to the vector’s rapid range shift and its adaptability to urban environments, driven by climate change [2]. Some existing antimalarial drugs suffer from side effects and limited efficacy. Importantly, resistance to available antiplasmodial drugs is rapidly rising worldwide, emphasizing the urgent need for discovery of new and effective targets [3]. Efforts in malaria control have emphasized drug development targeting the responsible parasites, Plasmodium spp. The two main agents of malaria are P. falciparum and P. vivax, where P. falciparum accounts for the majority of malaria-related deaths. However, persistent P. vivax infections in the liver pose significant challenges to both treatment and disease elimination efforts, leading to high morbidity rates [4]. While continuous culture of P. falciparum in its intraerythrocytic stage is possible, there is currently a shortage of continuous in vitro culturing system for P. vivax; experimentation requires constant replenishment of parasites from patient samples. This prompts the exploration of alternative approaches for assaying potential P. vivax drug target proteins. Surrogate genetics systems in the yeast Saccharomyces cerevisiae emerges as an attractive option due to the facile genetic engineering in this organism [5–7]. Target-based drug discovery strategies have proven to be effective in developing new effective medicines against infectious diseases [8]. One promising target for investigation is the enzyme deoxyhypusine synthase (DHS), which catalyzes the first step of post-translational modification of the eukaryotic translation factor 5A (eIF5A). In this process, the aminobutyl group is transferred from the polyamine spermidine to a specific lysine residue in eIF5A (K50 in H. sapiens eIF5A) [9], forming deoxyhypusine. Subsequently, the enzyme deoxyhypusine hydroxylase (DOOH) hydroxylates deoxyhypusine, leading to the biosynthesis of the unique amino acid hypusine. Notably, eIF5A is the only protein identified to contain this distinctive amino acid [9,10]. Furthermore, both eIF5A and DHS are essential for cell viability in eukaryotes [11–13], including pathogens [14–20]. Hypusinated eIF5A plays a role in various pathologies and physiological processes, contributing to the regulation of cancer [21–24], immune-related diseases [25], diabetes [26,27], neurological disorders [28], aging [29], and the replication of certain viruses [30]. Small molecules capable of modulating mammalian DHS activity through distinct mechanisms, including competitive [31] and allosteric inhibition [32], have already been described. These known inhibitors are often considered as candidates for future anti-cancer therapies [33,34]. Given that DHS is essential, it would be an attractive target for antiparasitic drugs, provided such drugs would be sufficiently selective for the parasite ortholog. However, inhibitors selective for parasite DHS are notably absent. This highlights the urgency to develop novel, targeted inhibitors specific for DHS from eukaryotic pathogens. Target-based drug discovery campaigns typically rely on in vitro biochemical assays, which require protein purification and lack a cellular context [8,35,36]. Alternatively, designing systems with genetically modified S. cerevisiae strains can provide efficient platforms for target-based drug discovery within a eukaryotic cell [5–7,37–39]. In this work, we established a yeast target-based platform dedicated to the identification of novel inhibitors of P. vivax DHS. We genetically engineered isogenic S. cerevisiae strains to differ only in their sole source of DHS, using either the orthologous gene from P. vivax or H. sapiens. Further enhancements were introduced into these strains to establish a robust system suitable for high-throughput screening, including expressing the target genes from a weak regulatable promoter, and genomic integration of genes encoding fluorescent proteins for precise quantification of cell proliferation. Additionally, genes related to pleiotropic drug resistance were deleted, to facilitate the entry of external molecules into the cells. Combined, these modifications resulted in a strain background ~60-fold more sensitive to the human DHS inhibitor GC7, compared to a human DHS-complemented strain previously generated by us [7] which lacks these genome editions. Using this system, we here identify three promising new small molecules preferentially targeting P. vivax DHS over its human counterpart. They are active in vitro against erythrocytic Plasmodium, and display low cytotoxicity. These newly discovered candidate inhibitors for P. vivax DHS can serve as initial leads for the development of potent inhibitors against the P. vivax DHS protein. Moreover, the system we have established for P. vivax DHS will be applicable to DHS from other parasites and to other parasitic drug targets. Results Homology modeling of Plasmodium vivax DHS Currently, no 3D protein structure is available for P. vivax DHS (PvDHS). To further explore the structural features of P. vivax DHS and conduct in silico screening of small molecule libraries for potential enzyme inhibitors of this enzyme, we used the YASARA [40] software to generate homology models of PvDHS. It is worth noting that all previously reported DHS structures are tetramers [7,41,42]. Moreover, DHS in B. malayi [7] and H. sapiens [32,41] are encoded by a single gene and exist as homotetramers. By contrast, DHS in trypanosomatids are heterotetramers, composed of two DHS paralogs [42]. Considering the structural similarities and the single-gene encoded PvDHS, we generated homotetramer models for this protein. Two models were selected for further investigation in our studies (S1 Fig). The first model, PvDHS-model 1 (S1A Fig), was constructed based on the deposited structure of H. sapiens DHS PDB ID: 6P4V [32], while the second model, PvDHS-model 2 (S1B Fig), was based on H. sapiens DHS PDB ID: 6PGR [32]. We developed these two models (S1A and S1B Fig) because 6P4V represents the structure in complex with the cofactor NAD+ and the competitive inhibitor GC7, while 6PGR is in complex with a ligand that induces a conformational change in which an α-helix is unfolded, forming a loop structure. Utilizing these models, our objective was to identify both competitive and/or allosteric inhibitors for PvDHS. SWISS-MODEL reported QMEAN scores for PvDHS-model 1 and PvDHS-model 2 were -2.62 and -3.45, respectively. In addition, the predicted local similarity based on the residue number revealed that residues from both binding sites were located in regions with estimated good quality (score ≥ 0.6) (S2 Fig). The enzyme core of PvDHS shares many features with its human homologue. In fact, the PvDHS protein sequence exhibits 59% similarity with the human DHS and 60% with S. cerevisiae DHS (Fig 1). Moreover, the residues in both the GC7 binding site and the allosteric site are conserved between HsDHS, ScDHS and PvDHS (as illustrated in Fig 1). However, PvDHS differs from the human and yeast DHS in their overall length. PvDHS has a total extension of 455 amino acids, making it 86 amino acids longer than HsDHS and 68 longer than ScDHS. Notably, these unique insertions are mainly located from the N-terminal to the middle of the protein extension (Fig 1). The larger insertion (residues 224 to 263) aligns with residues that form an alpha helix in the human enzyme (α8 in Fig 1). Another small insertion, located from residues 100 to 107, aligns with α3 in the human DHS. Currently, it remains unclear whether or how these extensions impact the PvDHS protein. Structure-based sequence alignment of H. sapiens DHS (HsDHS), P.vivax DHS (PvDHS) and S. cerevisiae DHS (ScDHS). Residues indicated by a light-colored background participate in the orthosteric binding site (blue), allosteric binding site (yellow), or both (green). Background coloring for PvDHS and ScDHS follows that of the HsDHS proteins. Residues indicated by a black background or framed in a box are conserved in all DHSs analyzed here. The secondary structure (α-helices and β sheets) shown in the top line are for HsDHS. Protein sequences and structures used in the alignment were: HsDHS (UniProt ID P49366, PDB ID 6P4V), PvDHS (UniProt ID Q0KHM1) and ScDHS (UniProt ID P38791). Molecular docking The compound library from the ChEMBL-NTDs database (https://chembl.gitbook.io/chembl-ntd/) was chosen for virtual screening of ligands toward PvDHS. This database comprises several compound libraries that have been tested in previous campaigns for neglected tropical diseases (NTDs) and Plasmodium drug discovery campaigns [43,44]. Initially, the dataset was manually curated and filtered, primarily selecting sets that had been previously filtered for compounds tested and found to be active in phenotypic assays against parasites, except for dataset 23 which was not pre-filtered. The datasets chosen for this study are listed in the Zenodo repository. The molecular library prepared from the ChEMBL-NTD database comprised 212,736 structures, accounting for different possible protonation states for each compound. Given the lack of specific inhibitors for P. vivax DHS, we predicted the binding sites based on co-crystallized ligands from human DHS structures (PDB IDs: 6P4V and 6PGR) [32], which served as the basis for the PvDHS models. We defined the binding residues for the known eukaryotic DHS spermidine mimic inhibitor, GC7 (PDB ID: 6P4V) [32], and of the human DHS allosteric ligand, 6-bromo-n-(1h-indol-4-yl)-1-benzothiophene-2-carboxamide (PDB ID: 6PGR) [32] to delineate the anchorage sites for the compounds to be screened. Molecular docking was performed in both the predicted binding sites of PvDHS, and the identified promising ligands were also docked into the HsDHS structures. Before performing the virtual screening, we validated the robustness of the docking protocol by re-docking the co-crystallized ligands, GC7 and 8XY [32] into the human DHS structures (PDB IDs 6P4V and 6PGR, respectively) (S3 Fig). The docking poses of both compounds precisely aligned with the crystal structure, with RMSD values of 0.205 Å for GC7 and 0.208 Å for 8XY, respectively (S3 Fig). The corresponding docking scores were approximately –6.0 kcal/ mol for both compounds. As these ligands are known potent inhibitors of DHS (GC7 IC50 = 0.14 μM and 8XY IC50 = 0.062μM) [32,45], this value was used as a cutoff threshold to identify new promising ligands, as described in the Methods section. Following the docking strategy (as described in the Methods section), we identified 100 and 85 promising hits (docking scores < - 6 kcal/mol) from the prepared structures in the ChEMBL-NTD database towards the orthosteric site (GC7 binding site) and allosteric site (8XY binding site) of PvDHS, respectively. The promising hits were also docked into the orthosteric or allosteric binding sites of the H. sapiens DHS protein structures, to assess the compound selectivity in silico. Based on the docking score values in PvDHS compared to HsDHS, free energy of binding values, and commercial availability, nine compounds (named N1 to N9), were selected as promising ligands for the PvDHS to be tested in yeast assays. The docking scores and free energy values for the ligands in both predicted binding sites of PvDHS and in HsDHS are listed in Table 1. 10.1371/journal.pntd.0012690.t001Table 1Docking score values obtained by molecular docking of the compounds in the PvDHS and HsDHS proteins.Compound generic namePvDHS (orthosteric site)PvDHS (allosteric site)HsDHS*Docking score (kcal/mol)Free energy of binding (kcal/mol)Docking score (kcal/mol)Free energy of binding (kcal/mol)Docking score (kcal/mol)Free energy of binding (kcal/mol) N1_o -7.685-48.32-4.872-33.58-5.086-38.60 N2_o -7.576-55.60-4.362-48.02-4.023-38.97 N3_o -7.214-44.07-5.064-48.65-3.815-42.46 N4_o -6.373-31.69-3.672-21.09-3.906-46.89 N5_o -6.097-37.68-4.811-25.10-1.790-27.24 N6_o -6.051-32.98-3.895-31.27-4.223-43.46 N7_a -5.888-33.24-9.081-34.35-4.611-39.12 N8_a -4.372-21.75-8.200-34.28-4.472-45.15 N9_a -6.697-40.34-7.530-47.74-4.189-35.32*: Compounds were docked into the human structures 6P4V (GC7 binding site) or 6PGR (allosteric site) based on which site yielded a higher docking score. N1_o to N6_o denote compounds docked in the orthosteric site and N7_a to N9_a represent compounds docked in the allosteric site. Docking score values obtained by molecular docking of the compounds in the PvDHS and HsDHS proteins. *: Compounds were docked into the human structures 6P4V (GC7 binding site) or 6PGR (allosteric site) based on which site yielded a higher docking score. N1_o to N6_o denote compounds docked in the orthosteric site and N7_a to N9_a represent compounds docked in the allosteric site. According to the docking results, compounds N1 to N6 (N1_o to N6_o in Table 1) were predicted to bind into the orthosteric site. As anticipated, similar to GC7 (S3 Fig), these compounds were positioned at the interface between subunits A and B of PvDHS (S4A–S4F Fig). The interaction profiles between the ligands N1_o to N6_o and the surrounding residues in subunits A and B within the active site of PvDHS are illustrated in S4A–S4F Fig. By contrast, compounds N7 to N9 (N7_a to N9_a in Table 1) were predicted to bind to the allosteric site of PvDHS (Table 1 and S4G–S4I Fig). The structures with the docked compounds are available in the Zenodo database. Establishment of a S. cerevisiae surrogate genetics platform for discovery of P. vivax DHS inhibitors The yeast S. cerevisiae shares conserved pathways with other branches of the eukaryotic phylogenetic tree, making it a valuable model for studying heterologous enzyme function [36,46]. Yeast surrogate genetics platforms, involving the functional replacement of essential genes in yeast by heterologous genes, have proven effective for infectious diseases drug discovery [5,37,39]. Furthermore, parallel functional complementation with the human and parasite counterparts of DHS offers a way to pinpoint small molecules that selectively modulate the pathogen’s protein [37]. To establish a reliable yeast platform to search for P. vivax DHS inhibitors, we constructed a mutant S. cerevisiae strain with three primary genetic modifications: 1) deletion of a transporter (Snq2) and transcription factors (Pdr1, Pdr3) involved in pleiotropic drug efflux; 2) insertion of fluorescent markers (mCherry, Sapphire); and 3) substitution of the endogenous gene encoding ScDHS (DYS1) with orthologous genes expressing PvDHS or HsDHS from a chromosomal locus. Modifications 2 and 3 were performed using CRISPR-Cas9 techniques, as described in the Methods section. Integrating these modifications into the yeast platform strain’s genome is crucial, particularly for large-scale experiments. This ensures more consistent expression of the newly integrated gene, thereby enhancing the reliability and reproducibility of our assay strategy [47]. We performed the genetic modifications using a yeast strain with deletions of PDR1, PDR3 and SNQ2 (HA_SC_1352control [48], S2 Table). PDR1 and PDR3 (Pleiotropic Drug Resistance) encode redundant transcription factors positively regulating the expression of various membrane transporters involved in pleiotropic drug resistance, while SNQ2 (Sensitivity to NitroQuinoline-oxide) encodes a plasma membrane ATP-binding cassette (ABC) transporter [49]. Deleting these genes simultaneously sensitizes yeast to a broad range of compounds, without compromising robustness [50]. For each strain, we inserted genes encoding different fluorescent proteins, mCherry or Sapphire, into the chromosomal CAN1 locus, to serve as markers for cell abundance. This enables precise monitoring of growth through fluorescence and turbidity measurements. Additionally, chromosomal expression of the markers reduces noise and overcomes copy number variations, compared to expression from plasmids [51]. Engineering the strains with fluorescent tags enables growth competition assays for different parasite targets with higher precision than using turbidity as the readout [48], allowing simultaneous evaluation of parasite target against the human equivalent within the same well [6]. Subsequently, we replaced the endogenous essential gene encoding ScDHS (DYS1) with the orthologous DHS genes from P. vivax or H. sapiens in the genome. The deletion of ScDHS was confirmed by western blot, as no band was detected with the anti-Dys1 antibody [52] for S. cerevisiae DHS (S5A Fig). ScDHS replacement was also confirmed by DNA sequencing. Moreover, PvDHS and HsDHS expressed in yeast were capable of catalyzing hypusination of the endogenous yeast eIF5A (S5A Fig), which demonstrates the functional complementation of the strains. Validation of the yeast experimental platform for DHS inhibitor identification Strains expressing HsDHS or PvDHS (SFS04 and SFS05, respectively; S2 Table) were tested for their ability to detect DHS inhibitors. To validate the platform, we conducted growth curves and western blot assays using GC7, a well-known inhibitor of human DHS [31]. In the newly generated strains, DHS expression was under transcriptional control of the MET3 promoter, which can be repressed by adding methionine to the culture media [53], enabling tunable control of DHS expression. We determined the methionine concentration at which hypusine levels were similar in the PvDHS and HsDHS complemented strains, and used this information to define the conditions for assaying the compounds selected by in silico screening. The growth of the dys1Δ strain expressing HsDHS was analyzed in 0, 60 and 130 μM methionine, and the PvDHS strain growth was assessed in 0 and 7.5 μM methionine (S5C and S5D Fig). The strain expressing PvDHS did not grow in methionine concentrations above 7.5 μM (S5B Fig). As expected from the greater evolutionary distance between Plasmodium and yeast, the level of hypusination in the strain complemented by PvDHS (approximately 40% at 0 μM methionine, S5C Fig) was lower than in the strain with HsDHS (approximately 60% at 0 μM methionine, S5C Fig), indicating that HsDHS complements the dys1Δ mutation more efficiently than does PvDHS. However, the hypusine levels in both strains were equal when HsDHS expression was regulated by 130 μM methionine (S5C Fig). Thus, we established growth conditions of the pre-cultures at 130 μM methionine for HsDHS and 0 μM methionine for PvDHS. It has previously been shown that reducing expression of the target protein in yeast sensitizes growth to inhibition by externally added compounds [5]. Therefore, we performed a growth curve assay to examine the effect of GC7 on the human DHS-complemented strain under various methionine concentrations (ranging from 0 to 130 μM). Notably, we observed a significantly more pronounced growth reduction by GC7 at 130 μM methionine (Fig 2A). To evaluate if the observed phenotype was indirectly associated with a reduction in the final product of the DHS-DOOH reaction, hypusine, we performed western blot analysis (Fig 2B). In addition, the western blot was used to test hypusine levels after addition of GC7 in the PvDHS-complemented strain, in the absence of methionine. This was defined based on the data presented in S5D Fig, indicating that the hypusine levels are similar between HsDHS and PvDHS under these conditions. As shown in Fig 2, treatment with 50 μM GC7 reduced hypusine levels (Fig 2B and 2C). GC7 inhibits growth of yeast strains, wt or dys1Δ complemented by HsDHS or PvDHS. (A) Comparison of inhibition caused by different concentrations of GC7 (as indicated) in dys1Δ yeast complemented by HsDHS (SFS04, S2 Table). The concentration of methionine used to regulate HsDHS expression is indicated in the figure. (B) Western blot detection of hypusination levels after 12 h of treatment with 50 μM GC7 in the wild-type (wt) and PvDHS and HsDHS-complemented strains. The methionine concentrations used in precultures (as mentioned in Material and Methods) are indicated in the figure. (C) Graph reporting the ratio between hypusinated eIF5A and total eIF5A under the conditions indicated in the figure. The bars represent mean of relative hypusination values ((hypusinated eIF5A/ eEF2) / total eIF5A/ eEF2)) ± standard deviation (SD; n = 3). A Student’s t-test was performed comparing the compound condition and the solvent control condition where an asterisk (*) indicates that the differences are statistically significant with 95% confidence (p < 0.05); two asterisks (**), 99% confidence (p < 0.01); three asterisks (***), 99.9% confidence (p < 0.001); ns, not statistically significant (p > 0.05). Yeast phenotypic assay using robotized platform Using the Eve robotized platform programmed for incubation, agitation, and plate reading cycles [6], we tested the PvDHS inhibition of the nine compounds selected through in silico screening (Table 1). Growth curve assays were performed (S6, S7 and S8 Figs) and metric parameters extracted from each curve. The area under the curve was selected for comparison of different compound concentrations and the DMSO solvent control (S9 Fig). In this in vivo assay, among the nine tested compounds two, N2 and N7, significantly reduced growth of the PvDHS- complemented strain compared to the strain complemented with HsDHS and the wt strain in the same genetic background (Fig 3). N2 and N7 detected as potential PvDHS selective inhibitors in the yeast-based assay. Relative area under the curve (AUC) of S. cerevisiae dys1Δ strains complemented by the indicated DHS enzymes, or of isogenic wt (ScDHS). The concentrations of the compounds range from 25 to 200 μM. Statistical significance levels indicated as in Fig 2. Each point represents the mean ± SD of experimental quadruplicates. The nine compounds were tested at concentrations ranging from 25 to 200 μM. When growth assays were performed with the PvDHS-complemented strain, six compounds reduced growth: N1, N2, N3, N5, N7 and N8. However, N1, N3, N5 and N8 reduced the growth of the HsDHS and wt strains at least to the same extent (S9 Fig). In contrast, N2 and N7 reduced growth of the PvDHS-complemented strain more than for the other strains (Figs 3 and S6–S9), indicating selectivity for PvDHS. Notably, N2 exhibited dose-dependent inhibition of the PvDHS-expressing strain, achieving a substantial 95% reduction in growth at 200 μM, 65% at 100 μM, 30% at 50 μM, and 13% at 25 μM of the compound (Fig 3). In contrast, this compound did not significantly affect the growth of HsDHS (p > 0.05, represented by the red bars in S9 Fig). Furthermore, N2 at 200 μM only led to a modest 17% reduction in the growth of the wt strain, expressing yeast DHS (illustrated by the green points in Fig 3). The selective growth reduction in the strain expressing PvDHS indicates that DHS is a major target of this compound. Compound N7 yielded a milder growth reduction phenotype, inhibiting approximately 30% of the growth of PvDHS-expressing strain at 100 μM. In comparison, the strain expressing yeast DHS showed 9% inhibition at the same concentration, and no statistically significant inhibition was observed for the HsDHS-expressing strain (Fig 3). Screening the Pathogen Box small-molecule library In an alternative approach, using the same robotized phenotypic screen, we tested 400 compounds from the Pathogen Box small-molecule library (Medicines for Malaria Venture) at a concentration of 25 μM against the PvDHS-complemented strain (SFS05, S2 Table). Most compounds did not affect the growth of the strains. However, 16 compounds (4% of the total molecules in the library) reduced the growth of the PvDHS-complemented strain (S10 Fig). Only few of these 16 compounds were readily commercially available, so we proceeded with confirmatory tests using new batches of compounds PB1 and PB2 (S4 Table). We confirmed growth inhibition of the PvDHS strain by PB1 in a follow-up growth curve assay; showing a dose-dependent response between 50 and 200 μM (Fig 4). With the fresh compound, PB1 reduced 30% of the growth of the PvDHS strain at 200 μM, and by 12% in the HsDHS strain (Fig 4). Relative growth of PvDHS and HsDHS strains in the presence of compound PB1 Growth curves were generated using different concentrations of PB1 (indicated in the figure) in the PvDHS (A) and HsDHS (B) strains. Each point represents the mean ± SD of four experimental replicates. (C) Relative growth score, calculated by the AUC with the compound in relation to the DMSO curve. Statistical significance levels indicated as in Fig 2. Hypusination is reduced by N2, N7 and PB1 in cells expressing PvDHS, but not HsDHS Finally, to verify whether the observed growth reduction phenotype in the yeast assay directly correlated with a decrease in the final product (hypusine) of the reaction of which DHS catalyzes the first step, we assessed the hypusination levels in the strains complemented with HsDHS, PvDHS, and the wt strain (SFS04, SFS05, and SFS01, respectively; S2 Table) following a 12 h treatment with the compounds. Specifically, hits from the yeast screening, including N2 (at 100 μM), N7 (at 50 μM), and PB1 (at 100 μM) were tested for their ability to inhibit hypusination in eIF5A (Fig 5). Hypusination of eIF5A in the presence of PvDHS inhibitor hits. (A) Detection by western blot of hypusination levels after 12 h of treatment with compounds indicated in the figure, at the following concentrations: GC7 (50 μM), N7 (50 μM) N2 (100 μM) and PB1 (100 μM). The methionine concentrations used in pre-cultures were 130 μM for HsDHS and 0 μM for PvDHS and WT. (B) Graph reporting the ratio between eIF5A hypusinated and total eIF5A under the conditions indicated in the figure. The bars represent the mean relative hypusination values ((hypusinated eIF5A / eEF2) / total eIF5A / eEF2)) ± SD (n = 3); except for GC7 where the bar represents the value for one experiment (n = 1). NT, not treated. A Student’s t-test was performed comparing the compound treated condition and the solvent control condition. Statistical significance levels indicated as in Fig 2. Compounds N7, N2, and PB1 significantly reduced hypusination levels in the PvDHS-complemented strain by 35% (p < 0.05), 60% (p < 0.05) and 70% (p < 0.01), respectively (Fig 5). Importantly, no reduction in hypusination was observed in the other tested strains (WT and HsDHS) following a 12 h treatment with these compounds, indicating that the inhibition was specific for PvDHS. Antimalarial activity To evaluate the antimalarial activity of compounds N2, N7 and PB1, we conducted concentration-response assays against the P. falciparum chloroquine-sensitive strain Pf3D7 and the drug-resistant strain PfDd2 (S11 Fig). The dose-response assays on the drug-resistant strain PfDd2 line yielded an EC50 of 0.2 ± 0.6 μM (S11A’ Fig) for compound N7; 9.4 ± 2 μM (S11B’ Fig) for compound N2, and 27 μM for compound PB1 (S11C’ Fig and Table 2). The EC50 values for strain Pf3D7 were 0.3 ± 0.7 μM, 34 ± 2.5 μM and interpolated to more than 20 μM for compounds N7, N2 and PB1, respectively (Table 2). 10.1371/journal.pntd.0012690.t002Table 2In vitro analysis of the antiplasmodial capacity of compounds against P. falciparum Dd2 (chloroquine-resistant) and 3D7 (chloroquine-sensitive).IDEC50 (μM) aPfDd2Pf3D7 N7 0.2 ± 0.60.3 ± 0.7 N2 9.4 ± 2.034 ± 2.5 PB1 27 ± 4.5>20 Artesunate 0.0015 ± 0.00050.0023 ± 0.001 Chloroquine 0.075 ± 0.0040.013 ± 0.003a EC50: half of the maximum inhibitory concentration in Pf3D7 and PfDd2 strains and their respective standard deviations. In vitro analysis of the antiplasmodial capacity of compounds against P. falciparum Dd2 (chloroquine-resistant) and 3D7 (chloroquine-sensitive). a EC50: half of the maximum inhibitory concentration in Pf3D7 and PfDd2 strains and their respective standard deviations. Cytotoxicity To assess the overall toxicity of N2, N7, and PB1, a metabolic viability assay was conducted in human cell cultures using the Presto Blue cell viability reagent (ThermoFisher Scientific), relying on the redox reaction of resazurin. The compounds were tested on two types of human cells: breast cancer cells (MCF7) and hepatocarcinoma cells (HepG2). Notably, compounds N2 and PB1 demonstrated no significant inhibition of cell viability at the tested concentrations (S12A and S12B Fig) indicating their potential for further drug development. Compound N7 exhibited a moderate toxicity for the tested cell lines, IC50 = 32 μM (S12C Fig). Discussion We have here established an S. cerevisiae surrogate genetics system for high-throughput screening to identify new parasite-selective inhibitors of P. vivax DHS. This approach was a further development of previous yeast surrogate systems designed for target-selective inhibitor searches designed to circumvent challenges associated with in vitro growth of parasites [5,38,39]. Utilizing CRISPR-Cas9 homology-directed repair, we have incorporated new features including fluorescent markers and genetic integration of the orthologous DHS genes, greatly enhancing the platform’s robustness and providing control over a wider range of target protein expression levels, using the weak regulatable MET3 promoter. Our newly generated strain, with DHS expression regulated by the MET3 promoter and reduced ABC exporter activity, exhibited enhanced sensitivity to external small molecules. This allowed growth inhibition at lower concentrations (15 μM) compared to previous studies using Leishmania major and H. sapiens DHS- complemented strains lacking these modifications, where 1 mM GC7 was required due to poor compound permeability [7]. This corresponds to a 60-fold improvement of sensitivity. There are limitations to our system, in that the readout proxy (cell proliferation) is only indirectly linked to the primary event (eIF5A hypusination). The dose-response relationship is therefore non-linear, and so the method is semi-quantitative. We can only use it in limited ranges of cell growth phase, inhibitor concentration, eIF5A hypusination etc. However, the method can be used to rank candidate inhibitors for their selectivity for the target protein parasite ortholog. To ensure the experimental conditions were as comparable as possible for both the HsDHS and PvDHS-complemented strains before testing compounds selectivity, we conducted preliminary assays to establish methionine concentrations yielding similar hypusination levels in each strain. HsDHS and PvDHS showed approximately 60% and 40% hypusination, respectively, at 0 μM methionine. We adjusted the methionine concentrations accordingly, 130 μM for HsDHS and 0 μM for PvDHS, to equalize the levels of hypusinated eIF5A, thus enabling a fair comparison during inhibitor screening. Here, with this established yeast-based platform, we screened a total of 409 compounds against PvDHS, including 400 molecules from the Pathogen Box library (Medicines for Malaria Venture) and nine compounds selected through virtual screening from a ChEMBL-NTD database. From this screening three compounds targeting PvDHS, based on their differential growth–N2, N7, and PB1 –were identified. The distinctive amino acid hypusine is the final product of the reaction catalyzed by the enzymes DHS and DOHH in the post-translation modification of eIF5A [13]. Hence, we performed a secondary assay to investigate whether these three compounds—N2, N7 and PB1—decreased the levels of hypusinated eIF5A. All three compounds significantly reduced the levels of S. cerevisiae hypusinated eIF5A levels selectively in the strain complemented by PvDHS, indicating preferential inhibition of the Plasmodium enzyme. Our molecular docking studies show that compound N2 binds the predicted orthosteric site of P. vivax, while N7 binds to the allosteric site. With a similar ligand interaction profile as GC7, N2 forms hydrogen bonds with the amino acids Gly395A, Glu404A and Lys410A, as well as a hydrophobic interaction with Trp408A. Additionally, unlike GC7, N2 exhibits a halogen bond with Asn192B via the chlorine atom. Predicted interactions for N7 include a halogen bond between the fluorine atom and Phe310A, a hydrogen bond with the side chain of Lys410A and multiple hydrophobic interactions, such as with Trp128A and Ile359A. No protein targets had been previously reported for these compounds. PB1 was identified through screening the Pathogen box rather than molecular docking. This compound was previously reported to have dual inhibitory activity in vitro against the Mycobacterium tuberculosis proteins EthR and InhA [54]. We now propose P. vivax DHS as a novel target for this small molecule. We tested these compounds in vitro against P. falciparum in an erythrocyte-based infection assay. N2 and PB1 exhibited EC50 in the low μM range against the drug-resistant P. falciparum Dd2 strain, whereas no cytotoxicity could be detected. N7 exhibited EC50 in the high nM range against both P. falciparum strains tested, and EC50 around 90 times higher in the human tested cell lines, demonstrating its potential as an antimalarial agent. The compounds identified showed selective inhibition for Plasmodium DHS in comparison to the human enzyme and were able to reduce intracellular levels of hypusine, indicating that DHS is one of the cellular targets of those compounds. In conclusion, here we report the development of an alternative approach for drug discovery based on S. cerevisiae strains genetically engineered for increased sensitivity to external small molecules and more stable target gene expression, designed against the promising protein target, PvDHS. These principles can be extended to other parasitic organisms and drug targets. Materials and methods Plasmids and strains Maintenance and cultivation of strains, preparation of culture media and solutions were conducted following standard protocols [55,56]. Plasmids and S. cerevisiae strains used in this study are listed in S1 and S2 Tables, respectively. The sequence of primers used are given in S3 Table. Synthetic compounds The well-established DHS inhibitor, GC7 [31,33,57], and nine compounds (here named N1 to N9), selected from in silico screening in this work, were purchased from different suppliers (S4 Table). Stocks of all compounds were prepared in DMSO at a concentration of 50 mM and stored at -20°C. The extended compound description is presented in S4 Table. Additionally, 400 small molecules from the Pathogen Box library (Medicines for Malaria Venture) were tested. The stocks of these compounds were at a concentration of 10 mM in DMSO (Sigma) and stored at -80° C. New batches of two compounds (named PB1 and PB2, S4 Table) from this collection were acquired for confirmatory testing. Virtual screening of the ChEMBL-NTD repository The 3D structures of the DHS protein from P. vivax were generated through homology-modelling using the YASARA software [40] and protein sequence retrieved from UniProt database (full length sequence; UniProt ID Q0KHM). Protein models quality were estimated using the SWISS-MODEL Structure assessment online platform [58]. For H. sapiens DHS, high-resolution crystallographic structures were readily available (PDB IDs: 6P4V and 6PGR [32]), which were utilized in the screening campaigns. The protein structures underwent preparation with the Protein Preparation Wizard (Schrödinger Release 2021–2: Schrödinger Suite 2021–2 Protein Preparation Wizard) [59] within the Maestro software (Schrödinger Release 2021–2: Maestro, NY, 2021), applying default parameters. Protein preparation included removing water molecules and ligands, addition of hydrogens, assigning bonds and bond orders, completing missing loops and/or side chains using Prime [60,61], and optimizing hydrogen bonding network by adjusting the protonation states of Asp, Glu and tautomeric states of His to match a pH of 7.0 ± 2.0. Subsequently, geometric refinements were conducted using the OPLS4 force field [62] in restrained structural minimization. Ligand structures were acquired from the ChEMBL-NTD database (https://chembl.gitbook.io/chembl-ntd/) in SDF format, and prepared using the LigPrep tool (Schrödinger Release 2021–2: Schrödinger Suite 2021–2, LigPrep) [59]. Ionization and protonation states were assigned in the pH range of 7.0 ± 2.0 using Epik [63] and energy minimization was performed with the OPLS4 force field [62]. Coordinates corresponding to the amino acids involved in the binding to the DHS inhibitor GC7 [13] and the allosteric inhibitor [32] were defined to generate the docking grid-boxes in the prepared protein structures. Molecular docking was executed using the Virtual Screening Workflow (Schrödinger Release 2021–2: Schrödinger Suite 2021–2, Virtual Screening Workflow Glide) [64], in the following selection stages: top 10% poses selected by Glide HTVS (high-throughput virtual screening) were used in the Glide SP (standard precision); top 10% poses from Glide SP were used in Glide XP (extra precision); and post-processing employing Molecular Mechanics with Generalized Born and Surface Area (MM-GBSA) method for the free energy of binding calculation using Prime [65]. In this strategy, we initially re-docked the co-crystalized ligands into the corresponding receptor protein upon which the PvDHS models were based. The docking score values of the co-crystalized ligands were employed as a cutoff threshold to consider new compounds as promising hits. Finally, we analyzed the free energy of binding values and the spatial disposition of the ligands within the binding sites to predict whether the compound would fit well within the receptor site. Construction of an S. cerevisiae DHS surrogate genetics platform We developed a yeast surrogate genetics platform by adapting previously described CRISPR/Cas9 methodologies [51,66]. S. cerevisiae strains with two primary modifications were created: chromosomal integration of sequences expressing the fluorescent proteins mCherry and Sapphire, and replacement of the essential gene DYS1 (which encodes DHS in S. cerevisiae) with DHS coding sequences from P. vivax or H. sapiens. These were integrated into the DYS1 locus in the genome of the S. cerevisiae working strain. The genetic background for generating these strains was the S. cerevisiae HA_SC_1352control strain [48] (S2 Table). This strain has deletions of PDR1 and PDR3, encoding transcription factors that regulate pleiotropic drug responses, as well as SNQ2, a membrane transporter of the ABC family [50]. Genomic integration of mCherry and Sapphire genes The coding sequences for the fluorescent proteins Sapphire and mCherry, under control of the TDH3 constitutive promoter, were inserted in the S. cerevisiae HA_SC_1352control strain into the CAN1 locus, using CRISPR/Cas9-mediated homology-directed repair [66]. sgRNA design, assembly and preparation The design, assembly, and preparation of the single guide RNA (sgRNA) targeting CAN1 locus were adapted from the Benchling platform (https://benchling.com/pub/ellis-crisprtools). We selected a previously reported sgRNA targeting CAN1 [66] (S3 Table). The oligonucleotides containing the guide sequences were annealed and cloned into the Bsm BI site of the sgRNA entry vector pWS082 (S1 Table) using Golden Gate assembly protocol [67]. This process replaced the GFP coding sequence from pWS082, generating the pWS082-CAN1 sgRNA construct (S1 Table). Half of the reaction mixture was used for transformation into E. coli 10-beta (New England Biolabs). White colonies (indicating the absence of GFP) were selected, and the pWS082-CAN1 sgRNA plasmid (S1 Table) was extracted using the GeneJet Plasmid miniprep kit (ThermoFisher Scientific). Accuracy of the cloning was confirmed through DNA sequencing. Yeast transformation We used a standard yeast transformation protocol [68] incorporating three DNA components: 300 ng of pWS082-CAN1 sgRNA vector, linearized by Eco RV digestion; 100 ng of the pWS172 previously digested with Bsm BI and 3 μg of PCR-amplified donor DNA. The donor DNA consisted of the mCherry/Sapphire sequences, with the addition of CAN1 homologous arms. This process generated the yeast strains SFS01 and SFS02 (S2 Table). Deletion of S. cerevisiae DYS1 and replacement by DHS from H. sapiens and P. vivax The coding sequences of DHS from H. sapiens (Gene ID: 1725, isoform A, here referred to as HsDHS) and P. vivax (Gene ID: 5476136, here referred to as PvDHS) were synthesized with codon usage optimization for expression in S. cerevisiae (S1 Text) and amplified by PCR using the oligonucleotides described in S3 Table. Subsequently, they were cloned into the Bam HI-Pst I sites of the yeast expression vector pCM188-MET3 (S1 Table), resulting in the generation of the following constructs: pCM188-MET3-HsDHS and pCM188-MET3-PvDHS (S1 Table). For details on all constructs generated in this study, including primer sequences, consult S1 and S3 Tables. The DNA constructs were used in this work for genomic integration protocols and for the yeast-based functional complementation system, and were verified by sequencing. sgRNA design, assembly and preparation The sgRNA targeting DYS1 was designed using the online platform ATUM (https://www.atum.bio/eCommerce/cas9) (S3 Table). The assembly and preparation process followed the same protocol described for CAN1 in this work, resulting in construction of the plasmid pWS082-DYS1 sgRNA. Yeast transformation The transformation reaction followed the same procedure as the integration of the fluorescent proteins into the CAN1 locus. However, the DNA components included in the reaction were as follows: 300 ng of pWS082-DYS1 sgRNA vector, linearized by EcoRV digestion; 100 ng of the pWS158 previously digested with BsmBI; and at least 5 μg of PCR-amplified donor DNA. The donor DNA comprised the MET3pr-DHS sequences from H. sapiens or P. vivax CYCt cassette, with the addition of DYS1 homologous arms. These linear fragments were transformed into strains SFS01 and SFS02 (S2 Table), generating strains SFS05 and SFS04 (S2 Table), respectively. To confirm genome integrations, colony PCR was conducted and DNA sequencing. Culture conditions The S. cerevisiae strains used in this work are described in Table 1. Synthetic complete (SC) medium (0.19% yeast nitrogen base without amino acids and ammonium sulfate, 0.5% ammonium sulfate, 2% glucose) with dropout of the appropriate amino acids was used for culture maintenance and assays performance. Validation of the platform in the presence of the drug GC7 Growth curves of yeast strains expressing DHS from H. sapiens (strain SFS04, S2 Table) or P. vivax (strain SFS05, S2 Table) were analyzed in the presence and absence of inhibitors. Prior to testing the inhibition by new compounds, we conducted an initial assay standardization using the well-known inhibitor of the human DHS enzyme, GC7 [31]. The assay was done in the presence of GC7 and different methionine concentrations added to the SC medium. With that, we aimed to evaluate GC7 inhibition across various levels of DHS expression. To prepare for the experiment, a 5 mL pre-culture was grown at 30°C under agitation until it reached approximately 1 × 107 cells/mL. Once this density was achieved, the pre-cultures were diluted to a concentration of approximately 1 × 106 cells/mL (OD600nm = 0.2). The cultures were then incubated under agitation for approximately 3 h until they entered the exponential growth phase (OD 600nm ~0.6). Just before the experiment, the cultures were diluted to OD600nm = 0.1 in the appropriate SC medium and dispensed in 200 μL aliquots per well in 100-well plates (Honeycomb plates, Labsystems Oy) using the automated OT2 robot pipettor (Opentrons). The strains were then cultivated for 72 h at low agitation, with absorbance values (OD450–600nm) measured every 20 min using the Bioscreen C plate reader equipment (Oy Growth Curves Ab Ltd). Phenotypic assays using a robotized platform The strains were cultivated in SC liquid medium, utilizing the optimal methionine concentrations determined through the growth validation assay. Cultures with a final OD600nm of 0.1 were dispensed into black 384-well plates (Greiner) using the Multidrop Combi reagent dispenser system (ThermoFisher). The compounds selected for virtual screening (S4 Table) were transferred to the plates using the Bravo Liquid Handling platform (Agilent) to final concentrations ranging from 25 to 200 μM for each compound (resulting in a final DMSO concentration of 1.25%) in a total volume of 80 μL. The cultures were incubated at 30°C, and their growth was monitored as previously described [6]. An automated platform was programmed for cycles of incubation, agitation, and plate reading using the Eve robot [6]. Fluorescence values (mCherry = 580 nm λexcitation / 612 nm λemission; Sapphire = 400 nm λexcitation / 511 nm λemission) and absorbance (OD600nm) were measured every 20 min over a period of 3 days using the BMG Polarstar plate reader. The experiments were conducted in two different experiments, each in quadruplicate. To visually assess growth reduction, growth curves were plotted using the mean of fluorescence values or absorbance, along with their respective standard deviations, derived from quadruplicate measurements. A solvent control sample was included in the same graph as a reference. A model was fitted, considering logistic growth model equations. The parameters relative to the curves were extracted using the Growthcurver package [69] in the R studio software (Version 2022 12.0 for Windows, Posit Software). The area under the curve (AUC) values were extracted for each curve and selected to calculate a relative score (relative growth = AUC compound / AUC DMSO). Student’s t-tests were conducted for four-sample comparisons, comparing the growth in the presence of compound with growth in solvent-only control. In a different approach, compounds from the Pathogen Box library (Medicines for Malaria Venture) were also tested in the strain complemented by PvDHS with the same methodology. The experiment was carried out in quadruplicate, in one experiment. The curves representing the means were plotted in the R software. Two candidates from this screen were selected for confirmation (S4 Table). Evaluation of hypusination levels by western blot assay The hypusination levels of the complemented strains were evaluated by western blot. The strains were cultured for approximately 14 h in SC medium without methionine. Pre-cultures were then diluted to OD600nm = 0.15 and grown during 10 h in fresh SC medium with different methionine concentrations. Cells were harvested by centrifugation at 4°C and stored at -80°C. For the assays in the presence of inhibitors, after 10 h of cell growth in SC medium with the specified methionine concentration, cells were washed and diluted again to OD600nm = 0.15 in SC medium lacking methionine. Inhibitor candidates were added at a concentration of 100 μM, except for compounds GC7 (inhibition control) and N7, which were added at a concentration of 50 μM. A control for 0% inhibition was also prepared, containing only cells and DMSO. After 12 h of treatment, cells were collected by centrifugation at 4°C and stored at -80°C. Cell pellets were resuspended in 40 μL of lysis buffer (200 mM Tris/HCl, pH 7.0, 2 mM DTT, 2 mM EDTA; 2 mM PMSF) and lysed by agitation for 10 min with glass beads. The cells were clarified by centrifugation at 20,000 × g for 15 min at 4°C, and the supernatant was collected. Protein quantification was performed using the BCA protein quantification assay (QPro BCA kit, Cyanagen) against a bovine serum albumin (BSA) calibration curve (Sigma Aldrich). A total of 12 μg of total protein was loaded onto a 12% SDS-PAGE gel and transferred to a methanol pre-activated PVDF membrane using a semi-dry transfer system (Bio Rad, catalog number 1704150) following the equipment’s standard protocol. The western blot employed the following antibodies: rabbit polyclonal anti-eIF5A (yeast) antibody at a 1:10,000 dilution; rabbit polyclonal anti-hypusine (Millipore) antibody at a 1:2,000 dilution; and a rabbit polyclonal anti-eEF2 (yeast) antibody at a 1:25,000 dilution (sample loading control) (ThermoFisher), followed by a secondary anti-rabbit antibody at a 1:20,000 dilution (Sigma Aldrich). The proteins of interest were detected using an enhanced chemiluminescence detection system (ECL, Amersham) on the Uvitec photodocumentation system (Alliance). The bands detected in the Western blot were quantified using GelAnalyzer 19.1 software [70]. The bands detected for anti-eIF5A and anti-hypusine were normalized in relation to the loading control bands (anti-eEF2), and the hypusination rate was calculated by dividing the values obtained for hypusinated eIF5A by the values quantified for total eIF5A. An F-test was performed to assess whether the variances were equivalent or different. Based on the known variance, a Student’s t-test was conducted to verify statistical significance of the data. P. falciparum cultures and in vitro antiplasmodial activity The antimalarial activity assay was assessed on P. falciparum 3D7 (chloroquine-sensitive), and Dd2 (chloroquine-resistant) [71]. The parasites were cultivated in RPMI 1640 medium (SIGMA-ALDRICH), supplemented with hypoxanthine 50 mg/L, glucose 2 g/L, sodium bicarbonate 2 g/L, O+ red blood cells (RBCs) and A+ human plasma 10%. The cultures were incubated at 37°C in a low oxygen environment (3% O2, 5% CO2, and 92% N2) as previously described by Trager et al. [72]. Drug inhibition assays were performed as previously described [73]. Briefly, synchronizations with 5% D-Sorbitol solution were performed at 48 h intervals before the experiments, to allow incubations with > 90% of the parasites in the ring stage. Assays were performed in a 96-well plate with 1% parasitemia and 2% hematocrit. Tests were carried out at concentration ranges from 0.01 to 80 μM and the EC50 values were determined. Artesunate and chloroquine were used as reference antimalarial drugs. After 72 h of incubation, parasitemia was assessed by fluorometry using SybrGreen fluorescent dye [74]. The plates were read in a Varioskan LUX Microplate Reader (ThermoScientific) by fluorescence at 490 nm excitation and 540 nm emission wavelengths. The growth inhibition values were expressed as percentages relative to the drug-free control and EC50 value were calculated by plotting Log dosing vs growth inhibition (expressed as percentage of the drug-free control) using GraphPad Prism (version 8.0). The experiments were carried out in three independent assays. Evaluation of cytotoxicity in mammalian cell lines Cell culture conditions The tumorigenic cell lines MCF7 (breast adenocarcinoma, ATTC: HTB-22) and HepG2 (hepatocellular carcinoma, ATCC: HB-8065) were cultivated in DMEM (Gibco DMEM, ThermoFisher Scientific) culture media supplemented with 10% fetal bovine serum (Gibco FBS, ThermoFisher Scientific) and 1% penicillin-streptomycin (PenStrep, ThermoFisher Scientific). The cell lines were incubated at 37°C with 5% CO2. Evaluation of cytotoxicity using resazurin assay Cell viability in the presence of compounds was assessed using the resazurin-based cell viability reagent, Presto Blue (Thermo Fisher Scientific). MCF7 and HepG2 cells were seeded into 96-well plates (TPP) at a concentration of 104 cells/well in 200 μL of culture medium and incubated for approximately 24 h until the cells adhered to the plate. The compounds selected as DHS inhibitor candidates in the yeast assay were added to the plates at concentrations ranging from 0.1 to 100 μM (with a maximum DMSO concentration of 0.4%) and incubated for 24 h. After this, 10% Presto Blue was added, and the cells were further incubated for 1 h. Resorufin fluorescence was measured at an excitation wavelength of 544 ± 15 nm and an emission wavelength of 590 ± 15 nm using the spectrofluorometer POLARstar Omega (BMG Labtech). Each experiment was conducted in duplicate, and the experiments were repeated twice. Cell viability percentages were determined by the quotient between the fluorescence intensity values of cells treated with the compounds by the values from solvent control cells, multiplied by 100. The concentrations that inhibited 50% of cell growth (IC50) were calculated through non-linear regression. The percentage of cell viability was plotted against the logarithmic concentration of the compounds using GraphPad PRISM software (version 8.0 for the Microsoft Windows operating system), and the results are represented as the mean ± standard deviation. Supporting information Homology models of P. vivax DHS homotetramer. (A) Cartoon representation of the PvDHS—model 1 (red) superposed on the HsDHS structure 6P4V [32] (blue). (B) Overlay of PvDHS—model 2 (yellow) superposed on the HsDHS structure 6PGR [32] (magenta). (C) Overlay of α-helix unfolded in PvDHS-model 2 (gray) with the corresponding position in PvDHS-model1 (green). (DOCX) Local quality assessment of residues in the PvDHS-model 1 and PvDHS-model 2. The black dashed line indicates the threshold distinguishing poor- and high-quality local similarity regions. Arrows indicate the position of the residues within the binding sites. (DOCX) Alignment of the re-docked ligands with its original co-crystallized conformation. Zoomed-out view of GC7 (pink) and 8XY (red) disposition in the tetramer structures 6P4V (A) and PDB ID: 6PGR (C), respectively. B and D show the overlay of the original ligands, GC7 (pink) and 8XY (red) with the ligands after redocking (gray). Different colors represent individual chains in the structure. (DOCX) Predicted binding mode of the selected compounds in PvDHS. The binding mode and interaction profile of the orthosteric ligands N1 to N6 (A to F, respectively; in orange, labeled in the figure) and allosteric ligands (N7 to N9, G to H, respectively) in PvDHS residues (gray). The residues from PvDHS that interact with the compounds are identified by the three-letter amino acid code followed by number and chain. Different type of interactions is represented by different colors and lines, and their corresponding meaning are described at the bottom of the figure. (DOCX) Hypusination of yeast eIF5A by H. sapiens and P. vivax DHS-complemented strains. (A) Western blot detection of hypusinated eIF5A and total eIF5A from the S. cerevisiae strains wt, dys1Δ::HsDHS and dys1Δ::PvDHS (SFS01, SFS04 and SFS05, S2 Table). An antibody specific for S. cerevisiae DHS (ScDHS) was used to show the deletion of the endogenous gene in the strains replaced by HsDHS and PvDHS. (B) Inhibition of growth of P. vivax DHS-complemented by different methionine concentrations. (C) Western blot detection of hypusination levels after 10 h of methionine treatment (concentrations indicated in the figure). (D) Semi-quantitative graph reporting the percentage of hypusinated eIF5A (hypusinated eIF5A/total eIF5A *100) under the conditions indicated in the figure. Bars represent mean ± standard deviation (n = 3) of the percentage of hypusinated eIF5A. (DOCX) Growth of yeast DHS deleted strain complemented by PvDHS in the presence of compounds N1 to N9. The strain used was SFS05 (S2 Table). The growth measurements were carried out in the Eve robot (see Materials and methods) and it is given in arbitrary fluorescence units (AFU) (mean ± SD, n = 4). Cell cultures were grown in SC–met and 1.25% DMSO or 0, 25, 50, 100 and 200 μM concentrations of the respective compound tested (see legend). (DOCX) Growth of yeast DHS deleted strain complemented by HsDHS in the presence of compounds N1 to N9. The strain used was SFS04 (S2 Table). The growth measurements, conducted in the Eve robot (see Materials and methods) are presented in arbitrary fluorescence units (AFU) and shown as mean ± SD, n = 4 replicates). Cell cultures were grown in SC with solvent alone (1.25% DMSO) or varying concentrations (0, 25, 50, 100 and 200 μM) of the respective tested compound, as indicated in the legend. (DOCX) Growth of yeast wt isogenic strain in the presence of compounds N1 to N9. The strain used was SFS01 (S2 Table). The growth measurements were carried out in the Eve robot (see Materials and methods) and it is given in arbitrary fluorescence units (AFU) (mean ± SD, n = 4). Cell cultures were grown in SC and solvent alone (1.25% DMSO) or varying concentrations or (25, 50, 100 and 200 μM) of the respective compound tested as indicated in the legend). (DOCX) Relative area under the curve extracted from growth curves. Bars represent the relative growth score of S. cerevisiae wt or dys1Δ strains complemented by the PvDHS or HsDHS enzymes. The compound concentrations range from 25 to 200 μM. Statistical significance levels indicated as in Fig 2. (DOCX) Growth reduction of PvDHS-complemented strain caused by compounds from the Pathogen Box. The strain used was SFS05 (S2 Table). The growth measurements were carried out in the Eve robot (see Materials and methods) and it is given in arbitrary fluorescence units (AFU) (mean ± SD, n = 4). Cell cultures were grown in SC–met and 1.25% DMSO or 25 μM of the respective compound tested (see legend). The compounds are named according to the Pathogen box compound ID. (DOCX) In vitro growth inhibition of asexual blood stage P. falciparum (3D7 or Dd2) for compounds N7, N2 and PB1. The inhibitory potential of different compounds was tested at concentrations ranging from 0.01 to 80 μM and the inhibition of parasitemia was measured after 72 hours of incubation. The growth inhibition values were expressed as percentages relative to the drug-free control and EC50 value were calculated by plotting log10 of compound concentrations vs growth inhibition (expressed as percentage relative to the drug-free control). The experiments were carried out in three independent assays. (DOCX) Cell viability analysis after treatment with compounds N2, N7 and PB. The compounds were tested at concentrations ranging from 0.1 to 100 μM, for 24 h in MCF7 and HepG2 cells, as indicated in the panels). Cell viability (%) was calculated as the ratio between cell incubated with compound and cell incubated with DMSO. Each point represents the mean ± standard deviation, with n = 2 replicates. (DOCX) Plasmids used in this study. (DOCX) Saccharomyces cerevisiae strains used in this study. (DOCX) Oligonucleotides used in this study. (DOCX) Synthetic compounds used in this study. (DOCX) Synthetic DHS genes with codon usage optimized for expression in Saccharomyces cerevisiae. (DOCX) 10 Jun 2024 Submitted filename: Rebuttal.pdf 13 Oct 2024 Dear Prof. Sunnerhagen, Thank you very much for submitting your manuscript "An experimental target-based platform in yeast for screening Plasmodium vivax deoxyhypusine synthase inhibitors" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments. We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation. When you are ready to resubmit, please upload the following: [1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. [2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file). Important additional instructions are given below your reviewer comments. Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts. Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments. Sincerely, Shaden Kamhawi Editor-in-Chief PLOS Neglected Tropical Diseases Shaden Kamhawi Editor-in-Chief PLOS Neglected Tropical Diseases *********************** Reviewer's Responses to Questions Key Review Criteria Required for Acceptance? As you describe the new analyses required for acceptance, please consider the following: Methods -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? -Is the study design appropriate to address the stated objectives? -Is the population clearly described and appropriate for the hypothesis being tested? -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? -Were correct statistical analysis used to support conclusions? -Are there concerns about ethical or regulatory requirements being met? Reviewer #1: The main concern on this manuscript is the incomplete characterisation of the system. As the pair of yeast strains expressing the human and the P. vivax DHS enzymes is presented as a tool to screen for DHS selective inhibitors, the direct quantification of the two yeast expressed DHS proteins by specific antibodies is a critical baseline parameter to a reliable measure of level and stability of the target transgenic enzymes. Setting the system baseline at the yeast culture conditions which produce similar levels of eIF5A hypusination in the two DHS producing strain - i.e. 130 microM Methionine (human DHS) vs no Methionine (Pv DHS) (Met is needed to repress the yeast MET3 transcription factor driving transgene DHS expression) may not correspond to achieving production of similar amounts of the two DHSs. In absence of a direct quantification, the possible presence of different enzyme levels may bias the quantification of respective inhibition and the assessment of selectivity. Also, as the system is based on measuring growth complementation of the yeast strains in which yDHS is replaced by either the human or the parasite DHS enzymes, the kinetics and extent of lethality induced by the addition of Methionine is important to evaluate reliability and comparability of the system phenotipic readout. Reviewer #2: The author's methods are sufficient for repeating the study and the methods used are appropriate to address the hypothesis. However, Western Blotting is not robust especially with a sample size of 3. The author's used a student's T-test for statistical consideration, but did not mention the distribution of their data. The authors should run two more blots for a total n of 5 and use a Shapiro-Wilk test to determine data distribution. The authors may then accurately assess which statistical test to consider. Reviewer #3: -Yes the objectives of the study clearly articulate the testible hypothesis mentioned. -Yes the study desig is appropriate -Yes the stastical analysis is corretly applied. -No concern about the ethical and regulatory requirments. Reviewer #4: I would like to congratulate the authors for this brilliant research they have conducted. They have designed an experimental target-based platform in yeast for screening P. vivax deoxyhypusine synthase inhibitors. This is the only protein known to contain the amino acid hypusine essential for cell viability in eukaryotes. Inhibiting DHS is a promising strategy to develop new therapeutic alternatives. No DHS inhibitors selective for parasite orthologs has previously been reported; They -Genetically modified saccharomyces cerevisiae strains expressing DHS genes from Homo sapiens (HsDHS) or P. vivax DHS (Pv DHS) in place of the Wild type endogenous gene from S. cerevisiae. They used inhibitors to assess the expression levels of these DHS genes. N2 exhibited dose-dependent inhibition of the PvDHS-expressing strain, achieving a substantial 95 % reduction in growth at 200 µM, 65 % at 100 µM, 30 % at 50 µM, and 13 % at 25 µM of the compound. In contrast, this compound did not significantly affect the growth of HsDHS (p > 0.05). Furthermore, N2 at 200 µM only led to a modest 17 % reduction in the growth of the wt strain, expressing yeast DHS. The selective growth reduction in the strain expressing PvDHS indicates that DHS is a major target of this compound. Question: The optimization and validation of this screening platform needs to be well defined with data to validate it. Why did the authors decide to stop at 7,5 uM for the PvDHS? The growth curve above this concentration is not shown and it would have been very important to consider other confounding factors of the parasite life stages. Will the DHS enzyme receptor have an effect on all the P. vivax life stages? In cases of mixed infections of P. falciparium, P vivax etc will the model still be valid? All of these were to be shown in the optimization data to generate concrete and impactful conclusions. -------------------- Results -Does the analysis presented match the analysis plan? -Are the results clearly and completely presented? -Are the figures (Tables, Images) of sufficient quality for clarity? Reviewer #1: The baseline complementation efficiencies of the two transgenic enzymes (in 0 Met) are fairly similar (40% and 60% of the parasite vs the human DHS). In this respect, the result that a 20fold higher Met concentration is required to repress the human vs the parasite enzyme should be discussed, raising questions on the actual levels of the different DHS produced in the two strains. Also, in the experiment testing the GC7 inhibitor on the human DHS strain, inspection of the control lanes (no GC7) shows that the intensity of the band of hypusinated eIF5A at 0 Met is virtually identical to that obtained at 130 microM Met (Figure 2B). The fact that, in contrast, the viability of the strain in the two conditions is very different (Figure 2A, no GC7 curves) questions the proposed link between yeast viability and levels of hypusilation. Reviewer #2: All figures are of sufficient quality. Assuming appropriate statistics were used (pending the data distribution test), the authors did well with graphical representation of all figures. I am slightly concerned with figure 5, as the relative abundance does not look correct. Specifically, the wild type PB1 bands appear identical in chemiluminescence, especially when normalizing to the loading control, compared to NT and N7 treatments. Is this a fault of the representative blot? Could the authors please supply the other two blots used in a supplementary file? Reviewer #3: -Yes the analysis match the analysis plan -Yes tghe results are clearly and completely presented -yes the quality of the figurs is the same. Reviewer #4: The results are clearly presented and stem from the methods used. However, as a question is raised in the methodology, the results are equally affected. Optimization results, and what happens in case of mixed infection. -------------------- Conclusions -Are the conclusions supported by the data presented? -Are the limitations of analysis clearly described? -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? -Is public health relevance addressed? Reviewer #1: The conclusion that the described two yeast strain system is ready to screen for selective inhibitors of Plasmodium vivax DHS is overstated. The characterisation of the baseline features of the biological system requires further experiments. Reviewer #2: The authors provide a short and sweet discussion summarizing their findings and discussing their model's future use. This is sufficient and appropriate. Reviewer #3: Yes the conclusion support the data. Reviewer #4: The conclusion is good and direct to the point based on the objective of the study carried out. -------------------- Editorial and Data Presentation Modifications? Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”. Reviewer #1: page 2: “Shortage of in vitro culture methods” is incorrect and too generic for the Plasmodium genus, whereas it is appropriate for P. vivax. page 3: Essentiality of DHS is overemphasized and incorrectly quoted. In reference to the pathogens (refs 14-16), an essential role is demonstrated only in the case of Trypanosome brucei; in P. falciparum, growth defects associated to the induced decreased amounts of PfDHS led to speculate of essentiality; finally, ref 16 does not contain experiments showing an essential role of DHS in the parasite studied there. page 4: The new strain is “approx 60-fold more sensitive to the human DHS inhibitor GC7” compared to? (the parental line, presumably). page 5: It is suggested to describe the key features of the parasite specific a.a. insertions in PvDHS compared to the yeast and the human DHSs: number, size, location in the primary sequence. page 9: It may be useful to mention the rationale for engineering the strain with two different fluorescent reporters; the use is incidentally mentioned in reference to the robotic screening. pages 10-11: See main comments above on the baseline features of the biological system. page 14: The description of hypusine as “the final product of the reaction catalysed by DHS” is slightly misleading; the DHS-DOOX two step pathway to produce hypusin-eIF5a was more accurately described in the Introduction. pag 15 – Figure 5: The remarkable increase in the level of yeast eIF5a hypusination induced by treatment with the inhibitors N2 and PB1 deserves attention and discussion. pag 16 – Discussion: Analysis and comments on the structure of the identified hits is expected in this section. In the case of N2 and N7, in comparison with those of the described human enzyme competitive and the allosteric inhibitors. In the case of PB1, which shows some structural similarity with the allosteric inhibitor of the human DHS, a comparison with the structural binding studies proposing its anti-tubercolosis activity could be worth mentioning. Reviewer #2: (No Response) Reviewer #3: Minor Revision with explanation Reviewer #4: - -------------------- Summary and General Comments Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed. Reviewer #1: The manuscript describes an interesting in vivo system using two S. cerevisiae strains respectively engineered with a human and a malaria parasite (P. vivax) enzyme, DHS, which catalyses the first step of a reaction leading to a unique conserved aminoacid modification, the hypusination of EIF5a. Proposing to ultimately identify selective parasite DHS inhibitors, the manuscript presents the use of the human DHS competitive inhibitor GC7 to validate the yeast system and aims to use the failure to complement the deleted yeast DHS in the two strains as a way to screen for selective inhibitors of the parasite DHS. The conclusion that the system is ready to screen for selective inhibitors of P. vivax DHS is however overstated in the absence of the characterisation of key baseline features of the biological system. Reviewer #2: Overall, the authors have completed what they set out to do. Figure 5 aside, they have done a great job in establishing a baseline yeast model for screening P. vivax drug targets. Given the lack of long-term in vitro culturing techniques available for vivax, this model is novel and has high impact potential. Reviewer #3: Authors have tried to identify inhibitors of DHS from Plasmodium vivax and used genetically modified Saccharomyces cerevisiae strains expressing DHS genes from Homo sapiens (HsDHS) or P. vivax (PvDHS) in place of the endogenous DHS gene from S. cerevisiae. The manuscript is interesting but requires some explanation. Authors are suggested to respond to the comments below and resubmit the manuscript. 1. Paragraph 2 of abstract: “This new strain background was -----" which new strain is authors referring to? 2. Why authors have not proposed the same experiments on P. falciparum as the invitro culture is easy? 3. Result 3 : Establishment of S. cerevisiae……Antibody details of ScDHS missing. 4. Why were the newly developed strains not checked for expression of Hs DHS and Pv DHS in the newly developed strains are specific antibodies available for the same? 5. Discussion should be detailed out more Reviewer #4: Authors should address the worries raised in the methodology -------------------- PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: Yes: NAMRATA ANAND Reviewer #4: Yes: Gabriel A Agbor Figure Files: While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Data Requirements: Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5. Reproducibility: To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols 8 Nov 2024 Submitted filename: Rebuttal.docx 12 Nov 2024 Dear Prof. Sunnerhagen, We are pleased to inform you that your manuscript 'An experimental target-based platform in yeast for screening Plasmodium vivax deoxyhypusine synthase inhibitors' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases. Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated. IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript. Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Shaden Kamhawi Editor-in-Chief PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 *********************************************************** 22 Nov 2024 Dear Prof. Sunnerhagen, We are delighted to inform you that your manuscript, "An experimental target-based platform in yeast for screening Plasmodium vivax deoxyhypusine synthase inhibitors," has been formally accepted for publication in PLOS Neglected Tropical Diseases. We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication. The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly. Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers. Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases